– USA, VA – Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to deliver oxygen to the areas where it is needed most, today announced the appointment of Jane Hollingsworth to its board of directors, effective immediately.
Jane will join the Nominating & Corporate Governance, Compensation and Audit Committees of the Board.
“Jane is a seasoned and accomplished executive who brings to our board considerable leadership experience and knowledge of the life sciences industry,” said Chairman and CEO, David Kalergis. “Additionally, her extensive public company experience as both an executive and a director will contribute to Diffusion’s growth plan. Jane will bring a valuable perspective to our board as we work to solve intractable medical problems, in particular in COVID-19 patients as we now are cleared by Romanian authorities to begin enrollment in the Romanian arm of our global COVID-19 clinical studies.”
Her appointment expands the board to seven directors.
Separately, the Company reported that full regulatory approval has been received from Romanian regulatory authorities to begin enrollment in its 24-patient, open-label lead-in Phase 1b clinical trial in hospitalized COVID-19 patients at the Romanian National Institute of Infectious Diseases.
About Jane Hollingsworth
Ms. Hollingsworth brings to Diffusion more than 25 years of experience in founding and leading life sciences companies. In 2013 she co-founded Militia Hill Ventures, a business focused on building, growing and investing in high-quality life sciences companies, and has served as its Managing Partner since that time.
“The strong foundational science and work done to develop that science to date has Diffusion well positioned for its next stage of growth. I look forward to helping the team take advantage of that foundation to bring new, better treatments to patients and great value to all Diffusion stakeholders,” commented Ms. Hollingsworth.
During her time at Militia Hill Ventures, Ms. Hollingsworth served as Executive Chair of Immunome Inc., a cancer immunotherapy company, and Talee Bio, a gene therapy company focused on cystic fibrosis that she co-founded. Prior to that she was co-founder and CEO of NuPathe Inc., a publicly-traded biopharmaceutical company focused on diseases of the central nervous system, and co-founder and EVP of Auxilium Pharmaceuticals, a biopharmaceutical company focused on urology and rare diseases. Ms. Hollingsworth began her career in the life sciences industry by serving as Vice President, Secretary and General Counsel of IBAH, Inc., a publicly-traded, multinational clinical research organization.
Ms. Hollingsworth received a B.A. from Gettysburg College and a J.D. from Villanova University.
About Diffusion Pharmaceuticals Inc.
Diffusion Pharmaceuticals Inc. is an innovative biotechnology company developing new treatments that improve the body’s ability to deliver oxygen to the areas where it is needed most, offering new hope for the treatment of life-threatening medical conditions. Diffusion’s lead drug TSC was originally developed in conjunction with the U.S. Office of Naval Research, which was seeking a way to treat multiple organ failure and its resulting mortality caused by low oxygen levels from blood loss on the battlefield. Evolutions in research have led to Diffusion’s focus today on addressing some of medicine’s most intractable and difficult-to-treat diseases, including multiple organ failure from respiratory distress, stroke and glioblastoma multiforme brain cancer. In each of these diseases, lack of available oxygen presents a significant obstacle for medical providers and is the target for TSC’s novel mechanism.
Diffusion is headquartered in Charlottesville, Virginia – a hub of advancement in the life science and biopharmaceutical industries – and is led by CEO David Kalergis, a 30-year industry veteran and company co-founder.
For more information: https://www.diffusionpharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.